Phase II clinical trial of CELYVIR in combination with chemotherapy for children and adolescents with refractory or relapsed solid tumors (Q3195981): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): Childhood cancer, despite being considered a “rare disease”, is the first cause of death due to disease, in Spain, until the age of 14, so there is an unmet need to develop new therapeutic strategies especially in solid tumors in relapse or refractory. Our Oncohematology unit of HUNJ, in collaboration with Dr. García Castro’s group at ISCIII, has accumulated a lot of experience in therapeutic applications of oncolytic adenoviruses. Especially in...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
Phase II clinical trial of CELYVIR in combination with chemotherapy for children and adolescents with refractory or relapsed solid tumors | |||
Revision as of 21:54, 12 October 2021
Project Q3195981 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II clinical trial of CELYVIR in combination with chemotherapy for children and adolescents with refractory or relapsed solid tumors |
Project Q3195981 in Spain |
Statements
41,500.0 Euro
0 references
83,000.0 Euro
0 references
50.0 percent
0 references
1 January 2018
0 references
31 March 2021
0 references
FUNDACION INVESTIGACION BIOMEDICA DEL HOSPITAL NIÑO JESUS
0 references
40°25'0.12"N, 3°42'12.89"W
0 references
28079
0 references
El cáncer infantil, a pesar de ser considerada una “enfermedad rara”, es la primera causa de muerte por enfermedad, en España, hasta los 14 años, por lo que existe una necesidad no satisfecha de desarrollar nuevas estrategias terapéuticas especialmente en tumores sólidos en recaída o refractarios. Nuestra unidad de Oncohematología del HUNJ, en colaboración con el grupo del Dr. García Castro en el ISCIII, ha acumulado mucha experiencia en aplicaciones terapéuticas de adenovirus oncolíticos. Especialmente en el desarrollo de un nuevo medicamento de Terapia Avanzada denominado CELYVIR, donde un adenovirus oncolítico se incorpora en células madre mesenquimales. Partiendo de resultados previos, clínicos y en modelos animales, sumamente esperanzadores, este proyecto trata de avanzar en el desarrollo de CELYVIR a través de la exploración de la combinación con otros tratamientos que se utilizan comúnmente en el tratamiento de recaídas y/o refractariedad. Además de avanzar en la comprensión del mecanismo de acción de CELYVIR, especialmente en la búsqueda de la confirmación de la activación inmune de los leucocitos infiltrantes del tumor por nuestro tratamiento. Objetivos todos ellos a desarrollar en el marco de una propuesta a la AEMPS de un Ensayo Cínico Fase II. (Spanish)
0 references
Childhood cancer, despite being considered a “rare disease”, is the first cause of death due to disease, in Spain, until the age of 14, so there is an unmet need to develop new therapeutic strategies especially in solid tumors in relapse or refractory. Our Oncohematology unit of HUNJ, in collaboration with Dr. García Castro’s group at ISCIII, has accumulated a lot of experience in therapeutic applications of oncolytic adenoviruses. Especially in the development of a new Advanced Therapy drug called CELYVIR, where an oncolytic adenovirus is incorporated into mesenchymal stem cells. Based on previous, clinical and highly hopeful animal models, this project seeks to advance the development of CELYVIR through the exploration of the combination with other treatments commonly used in the treatment of relapses or refractoryness. In addition to advancing the understanding of the mechanism of action of CELYVIR, especially in the search for confirmation of the immune activation of infiltrating tumor leukocytes by our treatment. Objectives to be developed in the framework of a proposal to the AEMPS for a Cynical Trial Phase II. (English)
12 October 2021
0 references
Madrid
0 references
Identifiers
PI17_02105
0 references